6 completed, 3 active not recruiting, 1 recruiting. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 3 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Thyroid cancer, Hurthle cell: new trials by email Literature Review of Thyroid cancer, Hurthle cell trials Research Report on Thyroid cancer, Hurthle cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer 177Lu-DOTA-EB-FAPI 1 radionuclide therapy, 177Lu-DOTA-EB-FAPI 2 radionuclide therapy, 177Lu-DOTA-EB-FAPI 3 radionuclide therapy - Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma | Phase 1 | Completed | The First Affiliated Hospital of Xiamen University | 12 | 2022-06-15 | 2025-04-01 |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 19 | 2020-09-02 | 2026-09-17 |
| Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate - Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Completed | Academic and Community Cancer Research United | 57 | 2018-02-07 | 2025-08-29 |
| Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer sorafenib, everolimus - Refractory Hurthle Cell Thyroid Cancer | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 35 | 2014-10-09 | 2026-02-11 |
| Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis - Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2013-05-08 | 2018-04-03 |
| IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation - Thyroid Cancer, Thyroid Neoplasms | Phase 2 / Phase 3 | Active not recruiting | University College, London | 504 | 2012-06-26 | 2026-05-07 |
| Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment Malignant Struma Ovarii, Papillary Thyroid Cancer | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 16 | 2011-09-20 | 2020-09-28 | |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 127 | 2010-09-09 | 2021-07-15 |
| A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer AMG 706 - Thyroid Cancer | Phase 2 | Completed | Amgen | 184 | 2005-07-01 | 2013-10-09 |
| Studies on Tumors of the Thyroid 68-Gallium Dotatate - Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2500 | 1977-06-01 | 2026-11-09 |
Adenocarcinoma, Follicular (9) · Thyroid Cancer, Papillary (9) · Thyroid Neoplasms (7) · Adenoma, Oxyphilic (1) · Carcinoma, Medullary (1) · Hypothyroidism (1) · Thyroid cancer, follicular (1)
Adenocarcinoma (9) · Adenocarcinoma, Papillary (9) · Carcinoma (9) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9) · Head and Neck Neoplasms (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Thyroid Diseases (9) · Thyroid Neoplasms (2) · Adenoma (1) · Carcinoma, Neuroendocrine (1) · Neoplasms, Ductal, Lobular, and Medullary (1)
Everolimus (1) · Lenalidomide (1) · Sodium Iodide (1) · Sorafenib (1) · cediranib (1) · dabrafenib (1) · gallium Ga 68 dotatate (1) · lenvatinib (1) · motesanib diphosphate (1) · pembrolizumab (1) · spartalizumab (1) · trametinib (1)
National Cancer Institute (NCI) (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Academic and Community Cancer Research United (1) · Alliance for Clinical Trials in Oncology (1) · Amgen (1) · Memorial Sloan Kettering Cancer Center (1) · The First Affiliated Hospital of Xiamen University (1) · University College, London (1)
United States (7) · Canada (1) · China (1) · United Kingdom (1)
Alan L Ho, MD, PhD (1) · Bryan R Haugen (1) · Chih-Yi Liao (1) · Eric Sherman, M.D. (1) · Haojun Chen, MD, PhD (1) · Joanna Klubo-Gwiezdzinska, M.D. (1) · Kong Y Chen, Ph.D. (1) · Manisha Shah (1) · Ujjal Mallick, MBBS MS FRCR (1)
PMID 18596272, PMID 20739388, PMID 28817373, PMID 33720068, PMID 35078345, PMID 40543520
N01CM00071 (2), N01CM00099 (2), U10CA180821 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00100 (1), N01CM62201 (1), P30CA014599 (1), P30CA015083 (1), P30CA016058 (1), UM1CA186705 (1)